Application of znf383 protein in preparation of products inhibiting p53 protein activity
A product, an active technology, applied in the field of biomedicine
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0096] Embodiment 1, the construction of plasmid and the preparation of oligomeric nucleic acid
[0097] 1. Construction of Myc-ZNF383 plasmid
[0098] The small fragment between the recognition sequences of the restriction endonucleases SalI and NotI of the pCMV-Myc plasmid was replaced with the DNA molecule shown in Sequence 2 in the sequence listing, and the resulting recombinant plasmid was the Myc-ZNF383 plasmid.
[0099] The Myc-ZNF383 plasmid expresses the ZNF383 protein shown in Sequence 1 in the Sequence Listing.
[0100] 2. Construction of Flag-p53 plasmid
[0101] The small fragment between the recognition sequences of the restriction endonucleases EcoRI and BamHI of the pCMV-Flag plasmid is replaced with the DNA molecule shown in sequence 4 in the sequence table, and the resulting recombinant plasmid is the Flag-p53 plasmid.
[0102] The Flag-p53 plasmid expresses the p53 protein shown in sequence 3 in the sequence listing.
[0103] 3. Preparation of oligonucleo...
Embodiment 2
[0110] Example 2, ZNF383 protein inhibits the activity of endogenous p53 protein in a dose-dependent manner
[0111] 1. Experiment 1
[0112] The experiment was repeated three times to take the average value, and the steps for each repetition were as follows:
[0113] 1. Cells (p53 + / + HCT116 cells or Hela cells) were seeded in 24-well plates containing 0.5 mL DMEM medium (8.0×10 per well 4 cells), and then placed at 37°C, 5% CO 2 Cultivate in an incubator, and when the fusion rate reaches 70-90%, they are randomly divided into four groups, and each group is set with three replicate wells, and the following treatments are carried out:
[0114] The first group: 20ng pG13L plasmid, 0.2ng pRL-TK plasmid and 0.4μg pCMV-Myc plasmid were added to each well for co-transfection;
[0115] The second group: add 0.1μg Myc-ZNF383 plasmid, 20ng pG13L plasmid, 0.2ng pRL-TK plasmid and 0.3μg pCMV-Myc plasmid to each well for co-transfection;
[0116] The third group: 0.2 μg Myc-ZNF383 p...
Embodiment 3
[0134] Example 3. ZNF383 protein depends on p53 protein to selectively down-regulate the expression of downstream apoptosis and immune-related target genes of p53 gene
[0135] 1. Experiment 1
[0136] The experiment was repeated three times to take the average value, and the steps for each repetition were as follows:
[0137] 1. Convert p53 + / + HCT116 cells were seeded in 6-well plates containing 2 mL of DMEM medium (2.0 × 10 per well 5cells), and then placed at 37°C, 5% CO 2 Culture in an incubator, and when the fusion rate reaches 70-90%, they are randomly divided into two groups, and each group is set with three replicate wells, and the following treatments are carried out:
[0138] Group 1: Add 2.0 μg pCMV-Myc plasmid to each well for co-transfection;
[0139] The second group: 2.0 μg Myc-ZNF383 plasmid was added to each well for co-transfection.
[0140] 2. 48 hours after step 1 was completed, the total RNA of each cell was extracted respectively, and then the first...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com